Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma

• Main Authors: Keisuke Okuno (Author), Caiming Xu (Author), Silvia Pascual-Sabater (Author), Masanori Tokunaga (Author), Haiyong Han (Author), Cristina Fillat (Author), Yusuke Kinugasa (Author), Ajay Goel (Author)
• Format: Book
• Published: MDPI AG, 2022-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Gemcitabine (Gem)-based chemotherapy is one of the first-line treatments for pancreatic ductal adenocarcinoma (PDAC). However, its clinical effect is limited due to development of chemoresistance. Various naturally occurring compounds, including Berberine (BBR), provide an anti-cancer efficacy with...